Can I Take Omega-3 (EPA/DHA) with CJC-1295?

What Is CJC-1295 and Why Are Women Using It?

CJC-1295 (also called modified GRF 1-29) is a synthetic analog of growth hormone-releasing hormone (GHRH). It is prescribed through 503A compounding pharmacies in the United States and is used off-label to stimulate pulsatile growth hormone (GH) secretion. It is not FDA-approved as a finished drug product.

Women are seeking CJC-1295 for a range of reasons tied directly to female physiology:

• Improving body composition during perimenopause and postmenopause, when estrogen decline accelerates visceral fat accumulation
• Supporting lean mass in women with PCOS-related insulin resistance
• Recovery and sleep quality, since GH is released primarily during slow-wave sleep
• Addressing the age-related GH decline that, in women, steepens around the menopause transition

How CJC-1295 Works in the Female Body

CJC-1295 binds the GHRH receptor in the pituitary gland, triggering GH pulses. Those pulses stimulate hepatic production of IGF-1. Early pharmacokinetic data in healthy adults showed that a single subcutaneous dose of 2 mcg/kg CJC-1295 increased mean GH concentrations 2- to 10-fold and IGF-1 by 1.5- to 3-fold over six days. That study included both men and women, though sex-stratified data were not published separately, which is a meaningful evidence gap you should know about.

Female sex hormones do modify GH axis physiology. Estrogen increases GH secretion but also reduces hepatic IGF-1 sensitivity, meaning the same GH pulse produces a lower IGF-1 rise in premenopausal versus postmenopausal women. A review in the Journal of Clinical Endocrinology and Metabolism confirmed that estrogen attenuates the IGF-1 response to GH stimulation, which is directly relevant if your clinician is titrating your CJC-1295 dose based on IGF-1 targets.

What Research Gaps Exist for Women Specifically

No published randomized controlled trials have examined CJC-1295 exclusively in women. All available human data are from mixed-sex early-phase studies. Dose recommendations you see online and in compounding prescribing guides are largely extrapolated from those small trials and from the broader GHRH analog literature. This is not a reason to avoid the peptide if your clinician has assessed your case, but it is a reason to track your own response carefully.

What Is the Omega-3 (EPA/DHA) Interaction with CJC-1295?

The combination produces a pharmacodynamic interaction, not a pharmacokinetic one. That distinction matters.

Pharmacokinetic vs. Pharmacodynamic: Why It Matters

A pharmacokinetic (PK) interaction means one substance changes how the body absorbs, distributes, metabolizes, or eliminates the other. There is no evidence that omega-3 fatty acids alter CJC-1295 absorption from subcutaneous injection, change its plasma half-life, or affect peptide degradation pathways. CJC-1295 with drug affinity complex (DAC) is cleared by enzymatic cleavage and renal filtration, not by CYP450 hepatic enzymes, which are the main targets of most PK interactions. Fish oil does not meaningfully inhibit or induce the enzymes involved.

A pharmacodynamic (PD) interaction means two agents produce overlapping or opposing biological effects, independent of each other's blood levels. This is the concern with CJC-1295 and omega-3.

The Two PD Overlap Areas

1. Antiplatelet activity

High-dose omega-3 fatty acids reduce platelet aggregation by incorporating into platelet membranes and shifting eicosanoid production away from thromboxane A2, a platelet-activating compound. A meta-analysis published in Arteriosclerosis, Thrombosis, and Vascular Biology found that omega-3 supplementation at doses of 3 g/day or higher produced clinically measurable reductions in platelet aggregation.

CJC-1295 itself does not directly inhibit platelets. GH and IGF-1, however, have downstream effects on coagulation factors. Recombinant human GH therapy in adults has been associated with modest changes in fibrinogen and coagulation factor VII, suggesting that GH axis activation touches hemostasis. The combination of omega-3-mediated antiplatelet activity with any GH-axis-mediated coagulation shift is theoretical in the context of CJC-1295 specifically, but the signal is worth noting, especially if you are also taking aspirin, NSAIDs, or anticoagulants like warfarin or apixaban.

2. Triglyceride and lipid effects

Omega-3 EPA and DHA lower serum triglycerides. The REDUCE-IT trial demonstrated that 4 g/day of icosapentaenoic acid (EPA) reduced triglycerides by approximately 19% and cardiovascular events by 25% in high-risk patients. Standard supplemental doses (1-3 g/day combined EPA+DHA) produce more modest TG reductions, typically 10-15%.

GH excess, as can occur with overstimulation of the GH axis, has been associated with shifts in lipoprotein metabolism, including changes in LDL particle size and HDL subfractions. A lipid panel before starting CJC-1295 and after 90 days gives you a meaningful baseline and a follow-up signal.

Bleeding Risk: Who Should Be Most Careful?

The practical bleeding concern from this combination is low for most women taking omega-3 at standard doses (<2 g EPA+DHA per day). It rises in specific situations:

Postmenopausal Women on Antiplatelet or Anticoagulant Therapy

Postmenopausal women have higher baseline cardiovascular risk and are more likely to be taking aspirin, clopidogrel, or direct oral anticoagulants (DOACs). Adding high-dose omega-3 on top of an existing antiplatelet drug, plus the theoretical hemostatic effects of GH-axis activation, stacks risk. If you are in this group, discuss both agents with your prescriber before continuing.

Perimenopausal Women with Heavy Menstrual Bleeding

Perimenopause is often accompanied by anovulatory cycles and irregular, heavy periods. Antiplatelet effects from high-dose omega-3 could worsen menorrhagia. This has not been studied specifically with CJC-1295, but the underlying physiology is plausible. Omega-3 supplementation has been shown in a small RCT to reduce dysmenorrhea severity, though its effect on menstrual blood volume at high doses is less clear.

Women Scheduled for Surgery or Egg Retrieval

The American Society of Anesthesiologists recommends stopping fish oil supplementation seven to ten days before elective surgery. If you are undergoing egg retrieval for IVF, your reproductive endocrinologist will guide you, though low-dose omega-3 is often continued through fertility treatment. CJC-1295 should be paused before any surgical procedure regardless, because GH axis effects on wound healing and fluid retention need to be considered.

Triglycerides, IGF-1, and Metabolic Monitoring for Women

Women with PCOS and perimenopausal or postmenopausal women carry disproportionate triglyceride burden relative to men at equivalent metabolic risk. Omega-3 addresses TG directly, which is a genuine benefit. The monitoring question is whether CJC-1295-driven IGF-1 elevation introduces any countervailing lipid signal that the omega-3 is masking or amplifying.

A practical monitoring framework for women combining both:

| Timepoint | What to check | Why | |---|---|---| | Before starting | Fasting lipids, IGF-1, CBC with platelets | Establish baseline | | 8-12 weeks after starting CJC-1295 | IGF-1 level | Confirm dose is in therapeutic range, not supraphysiologic | | 90 days | Fasting lipids | Detect any divergence from expected omega-3 TG benefit | | Ongoing, every 6 months | IGF-1, lipids | Sustained monitoring while on peptide therapy |

If your IGF-1 rises above the upper limit of the age-adjusted reference range for women, that is a signal to reduce CJC-1295 dose before attributing lipid changes to omega-3 alone.

Pregnancy, Lactation, and Contraception

CJC-1295 is contraindicated in pregnancy. This is not a precautionary gray area. There are no human safety data in pregnancy, and the pharmacological mechanism, stimulating the GH/IGF-1 axis, carries theoretical risks to fetal growth regulation and placental IGF-1 signaling. Animal reproductive toxicology data are absent from the published literature, which means we cannot rule out harm.

If you are trying to conceive, you must stop CJC-1295 before attempting pregnancy. There is no established washout period based on published data. Given that the DAC formulation of CJC-1295 has a half-life of approximately six to eight days, most clinicians recommend stopping at least four to six weeks before attempting conception, allowing multiple half-lives of clearance.

Omega-3 (EPA/DHA) is safe and encouraged in pregnancy. ACOG recommends that pregnant women consume at least 200 mg of DHA daily, and that supplementation is appropriate for women who do not eat two servings of low-mercury fish per week. Prenatal omega-3 is associated with reduced preterm birth risk and supports fetal neural development.

Lactation: No data exist on CJC-1295 transfer into breast milk. Because peptides can be present in milk and because the safety profile for nursing infants is entirely unknown, CJC-1295 should not be used during breastfeeding. Omega-3 DHA, in contrast, is actively secreted into breast milk and is beneficial for infant neurodevelopment. The American Academy of Pediatrics supports omega-3 intake during lactation.

Contraception: Women of reproductive age using CJC-1295 should use reliable contraception. Because CJC-1295 is not FDA-approved, there is no formal teratogen counseling program, but the mechanism justifies a consistent, effective method. Combined hormonal contraceptives remain appropriate; there is no known interaction between ethinyl estradiol-containing pills and CJC-1295, though estrogen's attenuation of IGF-1 response (described above) means your peptide dose may need adjustment if you start or stop hormonal contraception.

Who This Combination Is Right For, and Who Should Reconsider

Women Who Are Reasonable Candidates for Both

• Postmenopausal women with documented low IGF-1, elevated triglycerides, and body composition goals, under the care of an obesity medicine or endocrinology provider
• Perimenopausal women with metabolic syndrome features who are not on anticoagulation and do not have heavy menstrual bleeding
• Women with PCOS and elevated cardiovascular risk markers including high triglycerides, where omega-3 addresses one metabolic target and CJC-1295 addresses GH-axis insufficiency if documented

Women Who Should Reconsider or Pause One or Both

• Anyone currently pregnant or actively trying to conceive: stop CJC-1295 immediately
• Women taking warfarin, apixaban, rivaroxaban, clopidogrel, or daily aspirin at full antiplatelet doses: the additive bleeding signal warrants a conversation with your prescriber before continuing high-dose omega-3 alongside CJC-1295
• Women with active or history of GH-responsive tumors (acromegaly, active malignancy with IGF-1 sensitivity): CJC-1295 is generally contraindicated; omega-3 is not the concern here
• Women with bleeding disorders or pre-surgical windows: pause omega-3 per anesthesia guidelines and pause CJC-1295 in advance of any procedure
• Women breastfeeding: stop CJC-1295, continue omega-3

Dosing Windows and Practical Stacking Advice

Because the interaction is pharmacodynamic and not related to absorption timing, dose separation (taking the two at different times of day) does not reduce the pharmacodynamic risk. Bleeding risk from antiplatelet mechanisms is systemic and continuous, not tied to a dosing window.

What dose separation does help with is GI tolerance. CJC-1295 is injected subcutaneously, typically at night before sleep to coincide with the natural GH pulse. Omega-3 capsules taken with food reduce fish-oil-associated GI discomfort. Taking omega-3 with a meal and CJC-1295 at bedtime is a natural practical separation, but it is not doing anything to reduce the pharmacodynamic overlap.

Standard supplemental omega-3 doses of 1-2 g combined EPA+DHA per day are considered low-risk for bleeding in otherwise healthy adults, per a systematic review in the Journal of the American Heart Association. Staying in that range, rather than escalating to prescription-dose omega-3 (4 g/day as in Vascepa or Lovaza) without cardiovascular indication, is a reasonable risk-reduction step for women on CJC-1295.

PCOS and Omega-3 with CJC-1295: A Closer Look

Women with PCOS have a distinct metabolic phenotype: elevated androgens, insulin resistance, and dyslipidemia featuring high triglycerides and low HDL. Omega-3 addresses the dyslipidemia directly. A meta-analysis of omega-3 supplementation in women with PCOS found significant reductions in triglycerides (weighted mean difference: -27.42 mg/dL) and improvements in insulin sensitivity.

CJC-1295 is sometimes considered in PCOS when GH pulsatility is blunted, a pattern seen in the obese PCOS phenotype. The combination is not standard-of-care, and no trials have examined it in PCOS specifically. If you have PCOS and your provider is considering CJC-1295, the baseline lipid panel and IGF-1 are especially important because the PCOS-related dyslipidemia could confound your lipid response to either agent.

What to Tell Your Prescriber Before Combining These Two

Bring your full supplement list. Many women underreport supplements because they assume "natural" means inconsequential to a prescriber. Omega-3 at doses above 2 g/day is relevant clinical information for any provider managing a peptide protocol.

Specifically, your prescriber needs to know:

• The exact daily EPA+DHA dose you are taking, not just the total fish-oil capsule weight (a 1,000 mg fish-oil capsule often contains only 300 mg combined EPA+DHA)
• Whether you are on any other antiplatelet or anticoagulant medications
• Your most recent lipid panel, including triglycerides
• Your menstrual pattern if you are premenopausal or perimenopausal, particularly any history of heavy bleeding
• Your reproductive intentions for the next 12 months

The Endocrine Society's clinical practice guideline on adult GH deficiency is the closest published framework for GH-axis management, even though it addresses recombinant GH rather than secretagogues. Your provider should be familiar with IGF-1 target ranges from that guideline when titrating CJC-1295.

The Evidence Gap: What We Know Versus What We Are Extrapolating

To be direct with you: there are no published studies specifically examining the combination of CJC-1295 and omega-3 in any population, let alone in women. Everything in this article about their interaction is reasoned from:

1. The known pharmacology of each agent separately
2. The pharmacodynamic overlap between omega-3 antiplatelet effects and GH-axis hemostatic signaling
3. General principles of how GHRH analogs behave, drawn from trials with CJC-1295 and with tesamorelin (the FDA-approved GHRH analog)
4. The omega-3 safety literature, which is extensive and well-characterized

Tesamorelin, the only FDA-approved GHRH analog, has published RCT data showing lipid effects in HIV-associated lipodystrophy, including significant visceral fat reduction. Tesamorelin data offer the closest regulatory-grade reference point for a GHRH analog in adults. CJC-1295 is structurally similar but not identical, and the compounding formulations vary.

This evidence gap is not unique to WomanRx. No source can point you to a head-to-head trial on this specific combination. Any article that implies otherwise is overstating the data. The honest clinical position is: the combination is likely safe at standard omega-3 supplemental doses in healthy women without bleeding risk factors, requires monitoring, and requires stopping CJC-1295 before pregnancy.